{
    "clinical_study": {
        "@rank": "24893", 
        "arm_group": [
            {
                "arm_group_label": "adalimumab"
            }, 
            {
                "arm_group_label": "Etanercept"
            }, 
            {
                "arm_group_label": "infliximab"
            }, 
            {
                "arm_group_label": "Certolizumab"
            }
        ], 
        "brief_summary": {
            "textblock": "The rationale for this study is to further explore if development of antibodies against\n      TNF-\u03b1 blocking agents is associated with reduced clinical effect/worsened clinical outcome.\n      An important aspect of the study is to carry out an exploratory analysis of the\n      immunogenicity of the 4 recommended TNF-\u03b1 blockers in the treatment of RA in Denmark, using\n      the same cell-based assay."
        }, 
        "brief_title": "Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis (RA)", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "no sampling"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR\n             criteria.\n\n          -  Subjects who are planned to start treatment with ADA, ETA, CER or IFX\n\n          -  Subjects taking a minimum weekly dose of 7.5 mg of methotrexate\n\n        Exclusion Criteria:\n\n          -  Patients with compliance problems\n\n          -  Patients who have difficulties in reading and understanding local language\n\n          -  Patients with Juvenile Idiopathic Arthritis (JIA)\n\n          -  Azathioprine or cyclophosphamide treatment within 6 months before entering into the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients with Rheumatoid Arthritis (RA)"
            }
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691014", 
            "org_study_id": "B1801347"
        }, 
        "intervention": [
            {
                "arm_group_label": "adalimumab", 
                "description": "Study with 4 arms/groups with 36 patients per group. In total 144 patients.", 
                "intervention_name": "non-interventional study", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Etanercept", 
                "description": "Study with 4 arms/groups with 36 patients per group. In total 144 patients.", 
                "intervention_name": "non-interventional study", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "infliximab", 
                "description": "Study with 4 arms/groups with 36 patients per group. In total 144 patients.", 
                "intervention_name": "non-interventional study", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Certolizumab", 
                "description": "Study with 4 arms/groups with 36 patients per group. In total 144 patients.", 
                "intervention_name": "non-interventional study", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801347&StudyName=Formation%20of%20Antibodies%20and%20Subsequent%20Prediction%20of%20Clinical%20Response%20in%20Patients%20with%20Rheumatoid%20Arthritis%20Treated%20with%20four%20TNF%20Blockin"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "9000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarhus C.", 
                        "country": "Denmark", 
                        "zip": "8000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark", 
                        "zip": "6700"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frederiksberg", 
                        "country": "Denmark", 
                        "zip": "2000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hellerup", 
                        "country": "Denmark", 
                        "zip": "2900"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hillerod", 
                        "country": "Denmark", 
                        "zip": "3400"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Holbaek", 
                        "country": "Denmark", 
                        "zip": "4300"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolding", 
                        "country": "Denmark", 
                        "zip": "6000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense C", 
                        "country": "Denmark", 
                        "zip": "5000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randers N\u00d8", 
                        "country": "Denmark", 
                        "zip": "8930"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Svendborg", 
                        "country": "Denmark", 
                        "zip": "5700"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vejle", 
                        "country": "Denmark", 
                        "zip": "7100"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Viborg", 
                        "country": "Denmark", 
                        "zip": "8800"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "4", 
        "official_title": "FORMATION OF ANTIBODIES AND SUBSEQUENT PREDICTION OF CLINICAL RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH FOUR TNF BLOCKING AGENTS", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Anti-drug antibody levels and serum levels of active drug 6 months after initiation of treatment with adalimumab (ADL), certolizumab (CER), etanercept (ETA) or infliximab (IFX).", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of the association between the formation of antibodies to ADL, CER, ETA and IFX 6 months after initiation of treatment with ADL, CER, ETA or IFX and the clinical response 12 months after initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Anti-drug antibody levels 3 and 12 months after initiation of treatment with ADL, CER, ETA or IFX", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "measure": "Description of the association between the formation of anti-drug antibodies and concomitant methotrexate (MTX)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "DAS 28 3, 6 and 12 months after initiation of treatment with ADL, CER, ETA or IFX.", 
                "safety_issue": "No", 
                "time_frame": "3, 6 and 12 months"
            }, 
            {
                "measure": "HAQ score at baseline, 3, 6 and 12 months after initiation of treatment with ADL, CER, ETA or IFX.", 
                "safety_issue": "No", 
                "time_frame": "3, 6 and 12 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}